Chapter 2 76 Table S5. The relationship between PD-1T and clinicopathological variables as categories. PD-1T <90 per mm2 PD-1T ≥90 per mm2 n=69 n=51 Sex P=0.58 Male, no. (%) 34 (49%) 28 (55%) Female, no. (%) 35 (51%) 23 (45%) Age (years), median (IQR) P=0.96 63 (57 - 70) 64 (58 - 68) Smoking (never/ex/current) P=0.47 8/52/9 3/41/7 Pack years, median (IQR) P=0.18 25 (13 - 40) 30 (20 - 40) PS, no. (%) P=0.11 0 18 (26%) 18 (35%) 1 37 (54%) 28 (55%) ≥2 14 (20%) 5 (10%) Pathology, no. (%) P=0.20 Adeno 48 (69%) 28 (55%) Squamous 8 (12%) 13 (25%) LCNEC, NSCLC-type 2 (3%) 1 (2%) NSCLC, NOS 11 (16%) 9 (18%) Mutations, no. (%) P=1 KRAS positive 31 (45%) 20 (39%) KRAS negative 26 (38%) 17 (33%) KRAS unknown 12 (17%) 14 (28%) PD-L1 TPS, no. (%) Negative *P=0.04 47 (74%) 25 (63%) Positive ≥1% 22 (26%) 26 (37%) Negative <50% P=0.17 63 (91%) 42 (82%) Positive ≥50% 6 (9%) 9 (18%) Brain metastases, no. (%) P=0.22 15 (22%) 6 (12%) Treatment, no. (%) P=0.66 Nivolumab 53 (77%) 41 (80%) Pembrolizumab 16 (23%) 10 (20%) Line of treatment, no (%) P=0.21 1 1 (1%) 0 (0%) 2 53 (77%) 34 (67%) >2 15 (22%) 17 (%)
RkJQdWJsaXNoZXIy MTk4NDMw